Search results for "Tyro"

showing 10 items of 816 documents

Islet autoantibodies in Latvian subjects with non-insulin-dependent diabetes mellitus: slow-onset type 1 diabetes or polyendocrine autoimmunity?

2006

In Latvia diabetes mellitus is diagnosed using the WHO's clinical criteria; assays for the detection of autoantibodies are not available, and hence slowly progressive autoimmune diabetes is likely to be missed. Autoantibodies against glutamic acid decarboxylase (GAD65) and protein tyrosine phosphatase (IA-2) among patients with clinically diagnosed NIDDM identify group of patients with slow-onset type 1 diabetes or LADA. The aim of this study was to estimate the risk of polyendocrine autoimmunity among clinically diagnosed NIDDM patients from Latvia. One hundred NIDDM patients and 100 healthy controls were tested for GAD65 and IA-2 autoantibodies as well as 21-hydroxylase (21-OH) and tissue…

AdultMalemedicine.medical_specialtyendocrine system diseasesAdolescentTissue transglutaminasemedicine.medical_treatmentOverweightmedicine.disease_causeAutoantigensGeneral Biochemistry Genetics and Molecular BiologyAutoimmunityDiagnosis DifferentialHistory and Philosophy of ScienceInternal medicineDiabetes mellitusmedicineHumansReceptor-Like Protein Tyrosine Phosphatases Class 8ChildPolyendocrinopathies AutoimmuneAutoantibodiesProtein Tyrosine Phosphatase Non-Receptor Type 1Type 1 diabetesbiologybusiness.industryGlutamate DecarboxylaseGeneral NeuroscienceInsulinAutoantibodynutritional and metabolic diseasesMembrane Proteinsmedicine.diseaseLatviaIsoenzymesEndocrinologyDiabetes Mellitus Type 1Child Preschoolbiology.proteinFemalemedicine.symptomProtein Tyrosine PhosphatasesbusinessBody mass indexBiomarkersAnnals of the New York Academy of Sciences
researchProduct

Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation fo…

2005

Purpose In the era of molecular therapy of chronic myelogenous leukemia (CML) applying BCR-ABL tyrosine kinase inhibitors, the usefulness of molecular end points, in particular, quantitative polymerase chain reaction (PCR) for BCR-ABL in monitoring responses has been broadly accepted. Therefore, we have designed a prospective phase II trial in CML, which, for the first time, evaluated the feasibility and safety of molecular end points as surrogate markers to guide through a stratified treatment algorithm within a multicenter trial. Patients and Methods As a clinical model, we adopted minimal residual disease (MRD) found in relapse after allogeneic stem cell transplantation (SCT) in CML. For…

AdultOncologyCancer Researchmedicine.medical_specialtyTime FactorsMaximum Tolerated Dosemedicine.drug_classFusion Proteins bcr-ablGraft vs Host DiseaseAntineoplastic AgentsPolymerase Chain ReactionPiperazinesTyrosine-kinase inhibitorMyelogenousLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesMulticenter trialInternal medicinemedicineHumansTransplantation HomologousProspective Studiesbusiness.industryRemission InductionImatinibProtein-Tyrosine Kinasesmedicine.diseaseMinimal residual diseaseTransplantationPyrimidinesTreatment OutcomeImatinib mesylateOncologyBenzamidesImmunologyImatinib MesylateFeasibility StudiesbusinessStem Cell Transplantationmedicine.drugChronic myelogenous leukemiaJournal of Clinical Oncology
researchProduct

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid…

2008

Abstract Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is the standard of care for chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML after interferon-α (IFNα) failure enrolled 532 patients, 454 with a confirmed diagnosis of CP CML. Median time from diagnosis was 34 months; median duration of imatinib treatment was 65 months. Cumulative best rates of major cytogenetic response (MCyR) and complete cytogenetic response (CCyR) were 67% and 57%, respectively. At the 5-year landmark, 184 (41%) of the 454 patients are in CCyR. At more than 6 years, 199 (44%) of the 454 patients remain on imatinib. Most responses occurred within 12 mont…

AdultOncologymedicine.medical_specialtyTime FactorsAdolescentDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classImmunologyimatinib CML interferon-alphaSalvage therapyBlastic PhaseBiochemistryPiperazinesTyrosine-kinase inhibitorhemic and lymphatic diseasesInternal medicinemedicineHumansneoplasmsSurvival rateAgedAged 80 and overSalvage Therapybusiness.industryInterferon-alphaMyeloid leukemiaImatinibCell BiologyHematologyMiddle Agedmedicine.diseaseSurgerySurvival RatePyrimidinesTreatment OutcomeImatinib mesylateBenzamidesLeukemia Myeloid Chronic-PhaseDisease ProgressionImatinib MesylatebusinessFollow-Up StudiesChronic myelogenous leukemiamedicine.drug
researchProduct

Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome

2006

BACKGROUND Ovarian hyperstimulation syndrome (OHSS) is a life-threatening condition associated with ovarian stimulation. Its pathophysiology is unknown and its treatment continues to be empirical. Early (E)- and late (L)-OHSS occur in women at risk, though not in all cases. Vascular endothelial growth factor (VEGF) is related to increased vascular permeability in OHSS. We analysed the dynamics of the VEGF system in E- and L-OHSS. METHODS A prospective cohort of women undergoing IVF-ICSI treatment were divided into groups. E-OHSS: Nonpregnant patients classified as women not at risk (group 1) (n = 11) and patients at risk who did not (group 2) (n = 18) and did (group 3) (n = 8) develop sever…

AdultOvulationVascular Endothelial Growth Factor Amedicine.medical_specialtyTime Factorsmedia_common.quotation_subjectOvarian hyperstimulation syndromeVascular permeabilityOvaryFertilization in VitroBiologyCohort StudiesOvarian Hyperstimulation Syndromechemistry.chemical_compoundInternal medicineBlood plasmamedicineHumansalpha-MacroglobulinsSperm Injections IntracytoplasmicProspective cohort studyOvulationmedia_commonVascular Endothelial Growth Factor Receptor-1OvaryRehabilitationObstetrics and Gynecologymedicine.diseaseVascular endothelial growth factorEndocrinologymedicine.anatomical_structureReproductive MedicinechemistryOocytesFemaleSoluble fms-like tyrosine kinase-1Human Reproduction
researchProduct

Pleural Mesothelial Cells Express Both BLT2 and PPARα and Mount an Integrated Response to Pleural Leukotriene B4

2008

Abstract Leukotriene B4 (LTB4) plays a crucial role in the recruitment of neutrophils into the pleural space. We identified for the first time the mechanisms by which LTB4 interacts with mesothelial cells and recruits neutrophils in the pleural compartment. Primary pleural mesothelial cells express both the proinflammatory receptor for LTB4 BLT2, and the anti-inflammatory receptor for LTB4, PPARα. Parapneumonic pleural effusions highly increase BLT2 expression and, via BLT2 activation, increase the adhesion between mesothelial cells and neutrophils and the expression of ICAM-1 on mesothelial cells. The block of PPARα further increases both cell adhesion and ICAM-1 expression. BLT2 activatio…

Adultmedicine.drug_classLeukotriene B4Blotting WesternImmunologyReceptors Leukotriene B4Protein tyrosine phosphataseBiologyLeukotriene B4EpitheliumTyrosine-kinase inhibitorProinflammatory cytokinechemistry.chemical_compoundCell AdhesionmedicineHumansImmunology and AllergyPPAR alphaCell adhesionCells CulturedAgedInflammationLeukotriene B4 receptorPneumoniaMiddle Agedrespiratory systemFlow CytometryIntercellular Adhesion Molecule-1respiratory tract diseasesPleural EffusionChemotaxis LeukocyteNeutrophil InfiltrationchemistryImmunologyCancer researchPleuraPhosphorylationMesothelial CellThe Journal of Immunology
researchProduct

Tyrosine hydroxylase Val-81-Met polymorphism associated with early-onset alcoholism

2005

The present study examined the association of the Tyrosine hydroxylase Val-81-Met polymorphism with alcohol dependence. One hundred and fifty-nine patients in a psychiatric unit with alcohol dependence were genotyped as well as 92 healthy volunteers. The Val allele was more frequent in patients with alcohol dependence (69.5%) than in controls (62.5%). This effect was largely due to the association with early-onset alcoholism (77.8%), whereas no difference was noted between late-onset patients and controls. Our results suggest a role for tyrosine hydroxylase in early-onset alcoholism.

Adultmedicine.medical_specialtyGenotypeTyrosine 3-MonooxygenaseMutation MissensePolymerase Chain ReactionPolymorphism Single Nucleotidechemistry.chemical_compoundMethionineReference ValuesInternal medicineGenotypeGeneticsHumansMedicineMissense mutationAge of OnsetAlleleBiological PsychiatryGenetics (clinical)DNA PrimersEarly onsetMethionineBase SequenceTyrosine hydroxylasebusiness.industryAlcohol dependenceValineAlcoholismPsychiatry and Mental healthEndocrinologychemistryAge of onsetbusinessPolymorphism Restriction Fragment LengthPsychiatric Genetics
researchProduct

Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate

2017

Key Clinical Message Prompt ophthalmology evaluation and immediate imatinib suspension should be suggested at any time of tyrosine kinase inhibitor therapy in patients with visual deficit, as it may be a clinical manifestation of optic disk edema, and suspension may help in prompt recovery.

Adverse event0301 basic medicinegenetic structuresmedicine.drug_classOptic Disk EdemaLate onsetCase ReportClinical manifestationCase ReportsTyrosine-kinase inhibitor03 medical and health sciences0302 clinical medicinechronic myeloid leukemiatyrosine kinase inhibitorsmedicineIn patientAdverse effectbusiness.industryoptic disk edemaImatinibGeneral Medicineeye diseases030104 developmental biologyImatinib mesylateimatiniboptic nerve edemaAnesthesiaAdverse events030221 ophthalmology & optometrybusinessmedicine.drugClinical Case Reports
researchProduct

Characterization of an epithelial, nearly diploid liver cell strain, from Chinese hamster, able to activate promutagens

1987

Epithelial liver cells of the Chinese hamster (CHEL cells) were propagated in culture for 35 passages. At favourable cell densities, the population doubling time in normal medium, was 20 h. L-Tyrosine amino transferase activity was retained at a measurable level, but its enhancement by dexamethasone was detected solely in cells of early passages. Pyruvate kinase was strongly activated by fructose-1,6-biphosphate at low substrate concentrations. These enzymatic properties suggest that the CHEL cells are derived from a sub-population of parenchymal hepatocytes or from cells closely related to parenchymal hepatocytes. With a lag period of a few hours, CHEL cultures metabolized benzo[a]pyrene. …

Aflatoxin B1910-Dimethyl-12-benzanthraceneHealth Toxicology and MutagenesisPyruvate KinaseCellToxicologyEpitheliumChinese hamsterCricetulusAflatoxinsCricetinaeBenzo(a)pyreneGeneticsmedicineAnimalsDoubling timeBiotransformationCells CulturedGenetics (clinical)Tyrosine TransaminaseGeneticsbiologyLiver cellEpithelial CellsMonooxygenasebiology.organism_classificationMolecular biologyClone CellsEpoxide hydrolase activitymedicine.anatomical_structureLiverKaryotypingPloidyCell DivisionPyruvate kinaseMutagensMutagenesis
researchProduct

Nutraceutical properties of extra-virgin olive oil: a natural remedy for age-related disease?

2013

The health benefits of the Mediterranean diet can be largely ascribed to the nutraceutical properties of extra-virgin olive oil (EVOO). Mono-unsaturated fatty acids and various phenolic compounds, such as oleocanthal, oleuropein, hydroxytyrosol, and tyrosol, are the main nutraceutical substances of EVOO. These substances have been suggested to have the ability to modulate aging-associated processes. In experimental models, it has been shown that EVOO with high concentrations of polyphenols has anti-inflammatory and anti-oxidant properties. Indeed, it was observed that hydroxytyrosol and oleocanthal inhibit the cyclooxygenases (COX-1 and -2) responsible for prostaglandin production; oleurope…

Age-Related DiseaseAgingMediterranean dietAnti-Inflammatory Agentsmedicine.disease_causeAntioxidantschemistry.chemical_compoundNutraceuticalOleuropeinOleocanthalmedicineHumansPlant OilsFood scienceExtra-Virgin Olive OilOlive OilSettore MED/04 - Patologia GeneralePolyphenolsTyrosolchemistryPolyphenolDietary SupplementsHydroxytyrosolNutraceuticalGeriatrics and GerontologyOxidative stress
researchProduct

Redox reaction between amino-(3,4-dihydroxyphenyl)methyl phosphonic acid and dopaquinone is responsible for the apparent inhibitory effect on tyrosin…

2002

Amino-(3,4-dihydroxyphenyl)methyl phosphonic acid, the phosphonic analog of 3,4-dihydroxyphenylglycine, had been previously reported as a potent inhibitor of tyrosinase. The mechanism of the apparent enzyme inhibition by this compound has now been established. Amino-(3,4-dihydroxyphenyl)methyl phosphonic acid turned out to be a substrate and was oxidized to o-quinone, which evolved to a final product identified as 3,4-dihydroxybenzaldehyde, the same as for 3,4-dihydroxyphenylglycine. Monohydroxylated compounds (amino-(3-hydroxyphenyl)methyl phosphonic acid and amino-(4-hydroxyphenyl)methyl phosphonic acid) were not oxidized, neither was 4-hydroxy-l-phenylglycine. However, the relatively hig…

Alaninechemistry.chemical_compoundNon-competitive inhibitionChemistryStereochemistryTyrosinaseDopachromeSubstrate (chemistry)TyrosineBiochemistryRedoxQuinoneEuropean Journal of Biochemistry
researchProduct